Skip to content

Evaluation of the effect of immersive virtual reality-based upper extremity rehabilitation in hemiparesis and hemiplegia compared to standard therapeutic care: A randomized controlled trial.

Evaluation of the effect of immersive virtual reality-based upper extremity rehabilitation in hemiparesis and hemiplegia compared to standard therapeutic care: A randomized controlled trial.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
DRKS
Registry ID
DRKS00026242
Enrollment
112
Registered
2022-02-18
Start date
2022-02-17
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G81.0 G81.9 G81.1

Interventions

Group 1: Rehago complementary to standard therapeutic care. Patients perform the intervention daily (5 days per week, 30 min) at home and keep a diary of this activity. This takes place for a total of

Sponsors

ReHub GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: One of the following diagnoses: - ICD10 G81.0: Flaccid hemiparesis and hemiplegia. - ICD10 G81.1: Spastic hemiparesis and hemiplegia - ICD10 G81.9: Hemiparesis and hemiplegia, unspecified - First cerebrovascular brain injury (stroke) 3 to 12 months ago - Age range: 40-70 years - Ability to sit without support for more than 10 seconds - Ability to follow simple verbal instructions - No previous experience with Rehago or any other VR therapy app - Sufficient knowledge of German to operate the app - Explicit consent to participate in the study

Exclusion criteria

Exclusion criteria: - Symptomatic neurologic pre-condition, especially chronic progressive or recurrent like Multiple sclerosis or severe Muscle diseases - Heart failure - debilitating chronic dizziness - Impaired vision - Severe intellectual disability or dementia - Mental illness with delusional perceptual processing - Photosensitive Epilepsy - Bilateral pareses of upper extremity - Severe Aphasia that prevents the use of the therapeutic device

Design outcomes

Primary

MeasureTime frame
Functional Independence Measure (FIM) - all subgroups. Done on Day 0, 14, 28 and 42.

Secondary

MeasureTime frame
Adherence, EQ5D-5L, MMST, FMA, NNM. Adherence is documented daily via diary. EQ5D-5L is completed weekly by the patients. FMA and NNM are completed every 14 days (day 0, 14, 28, 42) with therapist(s) and patient(s). The Mini Mental State Test (MMST) will be administered on day 0 and day 42.

Countries

Germany

Contacts

Public ContactTheresa Kreidler

ReHub GmbH

t.kreidler@rehago.eu+49 341 989918-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026